Innovation in Pharmaceuticals: LPS antibody-based anti-bacterials
Powered by
Gain invaluable insights that can revolutionize your business
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData’s coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData’s proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating or maturing. This report specifically looks at innovation in LPS antibody-based anti-bacterials for the pharmaceuticals industry and the leading companies, start-ups and adoption trends. These insights help in making informed strategic decisions for a more durable source of competitive advantage
Innovation S-curve for Pharmaceuticals industry

Scope
Decode the key disruptive innovations impacting the pharmaceuticals sector, with specific focus on LPS antibody-based anti-bacterials and its trends in patent filing, identifying the leading companies and start-ups (and those with unicorn potential), key application areas plus examples from real-world scenarios and leading countries driving the innovation. In addition, we gauge the adoption trends in LPS antibody-based anti-bacterials, by analyzing funding/investing trends, demand for human capital/jobs, social media buzz, company filings, and the latest news in the area
Key Highlights
LPS antibody-based anti-bacterials: innovation landscape, patent filings trend, leading countries innovating, key application areas, top innovators, potential unicorns, real-world innovations, alternative dataset to track adoption trends using deals, jobs, social media, company filings, latest news, plus deep dive on key companies in LPS antibody-based anti-bacterials
Reasons to Buy
• Identify emerging, accelerating, and maturing innovations in the sector likely to be disruptive in the future
• Evaluate key companies at the forefront of these innovations and their disruptive impact
• Discover key start-ups innovating in the area and uncover those with unicorn potential
• Build strategic technology / product roadmaps to stay ahead of disruption through actionable intelligence
Pfizer Inc
Merck & Co Inc
Zoetis Inc
Sanofi
C. H. Boehringer Sohn AG & Co KG
SK Chemicals Co Ltd
Selecta Biosciences Inc
Nestle SA
Biological E Ltd
Molecular Templates Inc
National Research Council of Canada
Max-Planck-Gesellschaft
Hilleman Laboratories Pvt Ltd
Children's Medical Center
Novartis AG
Bharat Biotech Ltd
Intervet
IRCCS Policlinico San Donato
Johnson & Johnson
Table of Contents
Frequently asked questions

Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Pharmaceuticals reports
